var data={"title":"Carnitine supplements (Levocarnitine): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Carnitine supplements (Levocarnitine): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6451?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=carnitine-supplements-levocarnitine-drug-information\" class=\"drug drug_general\">see &quot;Carnitine supplements (Levocarnitine): Drug information&quot;</a> and <a href=\"topic.htm?path=carnitine-supplements-levocarnitine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Carnitine supplements (Levocarnitine): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187916\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Carnitor;</li>\n      <li>Carnitor SF;</li>\n      <li>G-LevoCarnitine S/F [OTC];</li>\n      <li>McCarnitine [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187917\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Carnitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059754\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442198\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Carnitine deficiency, treatment:</b> Limited data available: <b>Note:</b> Variability in genetic mutations and clinical presentations exist; dosage should be individualized based upon patient response and serum carnitine concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary deficiency:</i> Oral: Initial: 50 mg/kg/<b>day</b> in divided doses every 3 to 4 hours; titrate slowly as needed to 50 to 100 mg/kg/<b>day</b> in divided doses; some patients may require higher doses (up to 400 mg/kg/<b>day</b>) (Longo 2006; Magoulas 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Secondary deficiency (other inborn errors of metabolism):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Initial: 50 mg/kg/<b>day</b> in divided doses every 3 to 4 hours; titrate slowly as needed to 50 to 100 mg/kg/<b>day</b> in divided doses; some conditions may require higher daily doses (eg, 300 mg/kg/<b>day</b>) (K&ouml;lker 2011; Sutton 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 50 mg/kg as a single dose; titrate based on patient response. In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an equivalent dose given over the next 24 hours divided every 3 to 6 hours may be required; some conditions may require higher daily doses (eg, 300 mg/kg/<b>day</b>) (Sutton 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition, supplement:</b> Limited data available: Neonates (premature and term): <b>Note: </b>Neonates weighing &lt;5 kg are generally carnitine deficient and requiring supplementation: IV: Initial: 2 to 5 mg/kg/<b>day</b> in parenteral nutrition solution; higher doses up to 10 to 20 mg/kg/<b>day</b> may be necessary in patients with elevated triglyceride levels or receiving parenteral nutrition longer than 7 days; free and total plasma carnitine concentrations should be monitored and doses adjusted accordingly (ASPEN [Corkins 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059748\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=carnitine-supplements-levocarnitine-drug-information\" class=\"drug drug_general\">see &quot;Carnitine supplements (Levocarnitine): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Carnitine deficiency, treatment:</b> Infants, Children, and Adolescents: <b>Note:</b> Variability in genetic mutations and clinical presentations exist; dosage should be individualized based upon patient response and serum carnitine concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary deficiency:</i> Oral: Initial: 50 mg/kg/<b>day</b> in divided doses; may titrate slowly as needed to 100 mg/kg/<b>day</b> in divided doses; some patients may require higher doses (eg, 400 mg/kg/<b>day)</b> (Longo 2006; Magoulas 2012); maximum daily dose: 3,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosing interval (product specific):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral solution: Divided doses at evenly spaced intervals with or during meals (every 3 to 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Tablets: Divide daily dose into 2 to 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Secondary deficiency:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Initial: 50 mg/kg/<b>day</b> in divided doses; may titrate slowly as needed to 100 mg/kg/<b>day</b> in divided doses; some conditions may require higher daily doses (eg, 300 mg/kg/<b>day</b>); maximum daily dose: 3,000 mg/<b>day</b> (K&ouml;lker 2011; Sutton 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Dosing interval (product specific):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Oral solution: Divided doses at evenly spaced intervals with or during meals (every 3 to 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Tablets: Divide daily dose into 2 to 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-right:2em;\">IV: 50 mg/kg as a single dose; titrate based on patient response. In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an equivalent dose given over the next 24 hours divided every 3 to 6 hours, may be required; maximum daily dose: 300 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ESRD patients on hemodialysis:</b> Limited data available: Children and Adolescents: IV: 10 to 20 mg/kg dry body weight after each dialysis session; evaluate clinical response at 3-month intervals and titrate to the lowest effective dose. Therapy should be discontinued if no improvement after 9 to 12 months of therapy. <b>Note:</b> Current guidelines do not support the routine use of levocarnitine in dialysis patients (KDOQI Guidelines 2006; KDOQI Work Group 2009); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Valproic acid toxicity, acute:</b> Limited data available: Children and Adolescents: Dosing based on level of hepatic involvement and should be adjusted based on clinical response or serum level of valproic acid:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>No hepatotoxicity:</i> IV: 100 mg/kg/<b>day</b> divided every 6 hours until serum ammonia and valproic acid concentrations begin to decrease and clinical improvement is evident; maximum daily dose: 3,000 mg/<b>day</b> (Russell 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Symptomatic hyperammonemia or hepatotoxicity:</i> Reported dosing regimens variable: IV: Loading dose: 100 mg/kg, maximum loading dose: 6 <b>g</b>; followed by 50 mg/kg/dose (up to 3,000 mg/dose) every 8 hours <b>or</b> 15 mg/kg/dose every 4 hours; continue treatment until serum ammonia concentrations begin to decrease and clinical improvement is evident; patients may require several days of therapy (Perrott 2010; Russell 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyclic vomiting syndrome, prevention:</b> Limited data available: Children and Adolescents: Oral: 50 to 100 mg/kg/<b>day</b> in divided doses 2 to 3 times daily; maximum dose: 1,000 mg/dose (Li 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary carnitine deficiency:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral solution: Initial: 1,000 mg daily in divided doses (spaced every 3 to 4 hours throughout the day); titrate slowly as needed to 1,000 to 3,000 mg per day in divided doses; higher doses may be needed in some patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablets: Oral: 990 mg 2 to 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 50 mg/kg; titrate based on patient response. In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an equivalent dose given over the next 24 hours (divided every 3 or 4 hours, never less than every 6 hours) may be required. Maximum daily dose: 300 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ESRD patients on hemodialysis:</b> IV: 20 mg/kg after each dialysis session; evaluate clinical response at 3-month intervals and titrate to the lowest effective dose. Therapy should be discontinued if no improvement after 9 to 12 months of therapy. <b>Note:</b> Current guidelines do not support the routine use of levocarnitine in dialysis patients (KDOQI guidelines 2000); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Safety and efficacy of oral carnitine have not been established in ESRD. Chronic administration of high <b>oral</b> doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of <b>potentially toxic </b>metabolites.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187896\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitor: 200 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/mL (5 mL [DSC], 12.5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitor: 1 g/10 mL (118 mL) [contains methylparaben, propylparaben; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitor SF: 1 g/10 mL (118 mL) [sugar free; contains methylparaben, propylparaben, saccharin sodium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">G-LevoCarnitine S/F: 1 g/10 mL (474 mL) [sugar free; contains methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/10 mL (118 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitor: 330 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">McCarnitine: 330 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 330 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187881\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059758\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: May be taken directly or diluted in either beverages or liquid food; consume slowly; doses should be spaced evenly throughout the day, preferably during or following meals (every 3 to 4 hours) to improve tolerance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Dependent upon use:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Carnitine deficiency: May be administered undiluted (200 mg/mL) as IV push over 2 to 3 minutes <b>or</b> further dilute and administered as IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD on hemodialysis: May be administered undiluted (200 mg/mL) IV push over 2 to 3 minutes into the venous return line</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Valproic acid toxicity: May be administered undiluted (200 mg/mL) IV push over 2 to 3 minutes or further dilute and administered IV infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187912\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV solution is stable for up to 24 hours when mixed in NS or LR in PVC bags and stored at 25&deg;C (77&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059757\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Solution, tablets: Treatment of primary or secondary carnitine deficiency (FDA approved infants, children, and adults); has also been used in cyclic vomiting syndrome for the prevention of episodes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of secondary carnitine deficiency and  prevention and treatment of carnitine deficiency in patients undergoing dialysis for end-stage renal disease (ESRD) [FDA approved in pediatric patients (age not specified) and adults]; has also been used for treatment of valproic acid toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187954\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">LevOCARNitine may be confused with levETIRAcetam, levocabastine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187952\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Atrial fibrillation (intravenous), chest pain (intravenous), ECG abnormality (intravenous), hypertension (intravenous), palpitations (intravenous), peripheral edema (intravenous), tachycardia (intravenous), vascular disease (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Depression (intravenous), dizziness (intravenous), drug dependence (intravenous), headache (intravenous), paresthesia (intravenous), vertigo (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypercalcemia (intravenous), parathyroid disorder (intravenous), weight gain (intravenous), weight loss (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain (intravenous), anorexia (intravenous), diarrhea (intravenous), dysgeusia (intravenous), gastritis (intravenous), gastrointestinal disorder (intravenous), melena (intravenous), nausea (intravenous), vomiting (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (intravenous), hemorrhage (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Amblyopia (intravenous), eye disease (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal failure (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchitis (intravenous), cough (intravenous), rhinitis (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Accidental injury (intravenous), body odor, fever (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abdominal cramps, change in prothrombin time, hypoglycemia, myasthenia (uremic patients), rhabdomyolysis, seizure, vitamin K deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14725394\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to levocarnitine or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187885\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal effects: GI reactions may result from too rapid consumption of oral carnitine; consume oral solution slowly and space doses evenly throughout the day to maximize tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carnitine deficiency: Risk factors include: Age (infants and young children are deficient in the enzyme that activates carnitine), chronic valproic acid administration, concomitant neurologic disorders, congenital metabolic disorders, hepatic cirrhosis, renal failure, critical care patients (burns, sepsis, trauma, organ failure), use of multiple antiepileptic drugs and other drugs (chemotherapy agents, antinucleoside analogues) (Katiyar 2007). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of potentially toxic metabolites. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorder: Use with caution in patients with seizure disorders or in those at risk of seizures; both new-onset seizure activity as well as an increased frequency and/or severity of seizures has been observed. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022070\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Routine prophylactic use of carnitine in children receiving valproic acid to avoid carnitine deficiency and hepatotoxicity is probably not indicated (Freeman, 1994).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299590\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221274\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13119&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): LevOCARNitine may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187892\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187904\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal studies. Carnitine is a naturally occurring substance in mammalian metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059753\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carnitine serum concentrations should be obtained at baseline and  subsequently monitored weekly to monthly. In metabolic disorders: Blood chemistry, vital signs, and plasma carnitine concentration. In ESRD patients on dialysis: National Kidney Foundation guidelines recommend basing treatment on clinical signs and symptoms; evaluate response at 3-month intervals and discontinue if no clinical improvement noted within 9-12 months (Eknoyan, 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproic acid toxicity: Serum valproic acid concentrations (every 4-6 hours until a downward trend is observed), electrolytes, blood gases, mental status, hepatic function, serum ammonia concentration, serum lactate, and platelets</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059756\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma free carnitine level: &gt;20 micromoles/L; plasma total carnitine level 30-60 micromoles/L; to evaluate for carnitine deficiency determine the plasma acylcarnitine/free carnitine ratio (A/F ratio) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">A/F ratio = [plasma total carnitine - free carnitine] divided by free carnitine </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Normal plasma A/F ratio = 0.25; in carnitine deficiency A/F ratio &gt;0.4</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187884\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Carnitine is a naturally occurring metabolic compound which functions as a carrier molecule for long-chain fatty acids within the mitochondria, facilitating energy production. Carnitine deficiency is associated with accumulation of excess acyl CoA esters and disruption of intermediary metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187901\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; Major metabolites: Trimethylamine (TMA) and trimethylamine N-oxide (TMAO)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral solution: 15.9% &plusmn; 4.9%; Tablet: 15.1% &plusmn; 5.3%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 17.4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 3.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (76%, 4% to 8% as unchanged drug); feces (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187903\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acticarnitine SF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (474 mL): $23.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Carnitor Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (5 mL): $39.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Carnitor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (118 mL): $39.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Carnitor SF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (118 mL): $49.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevOCARNitine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (118 mL): $46.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Carnitor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (90): $106.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (L-Carnitine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (90): $31.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LevOCARNitine (Dietary) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (90): $28.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LevOCARNitine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (90): $98.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (McCarnitine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (90): $15.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187906\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abedine (JP);</li>\n      <li>Albicar (AR);</li>\n      <li>Almiba (UA);</li>\n      <li>Bio-Carnitine (BE);</li>\n      <li>Biocarn (CH, DE);</li>\n      <li>Branigen (IT);</li>\n      <li>Cardimax (PH);</li>\n      <li>Cardispan (MX);</li>\n      <li>Carnicor (ES, PH);</li>\n      <li>Carnil (GR, RO);</li>\n      <li>Carnin (KR);</li>\n      <li>Carnitene (CH, HR, NL, TW);</li>\n      <li>Carnitina (AR);</li>\n      <li>Carnitor (BD, GB);</li>\n      <li>Carnivit (PL);</li>\n      <li>Carry FA (KR);</li>\n      <li>Cartan (CN);</li>\n      <li>Cartin (PH);</li>\n      <li>Cartine (BD, PH);</li>\n      <li>Chudex (PL);</li>\n      <li>Disocor (PT);</li>\n      <li>Efe-Carn (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Elcarnitol (CH);</li>\n      <li>Entomin (JP);</li>\n      <li>Fitmax L-Karnityna (PL);</li>\n      <li>Hardbody L-Karnityna (PL);</li>\n      <li>Karniten (UA);</li>\n      <li>L-Cadul (KR);</li>\n      <li>L-Carn (KR);</li>\n      <li>L-Carnitin (AT, CZ, PL);</li>\n      <li>L-Cartin FF (JP);</li>\n      <li>L-Karnityna (PL);</li>\n      <li>Lecarna (MT);</li>\n      <li>Levocar (BD);</li>\n      <li>Levocarnil (FR);</li>\n      <li>Monocamin (JP);</li>\n      <li>Nefrocarnit (EE, TR);</li>\n      <li>Neurex (AR);</li>\n      <li>Neuroactil (AR);</li>\n      <li>Ocarnix (BD);</li>\n      <li>Secabiol (ES);</li>\n      <li>Steatel (UA);</li>\n      <li>Trian (TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bonner CM, De Brie KL, Hug G, et al, &ldquo;Effects of Parenteral L-Carnitine Supplementation on Fat Metabolism and Nutrition in Premature Neonates,&rdquo; <i>J Pediatr</i>, 1995, 126(2):287-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/7844680 /pubmed\" target=\"_blank\" id=\"7844680 \">7844680 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borum PR, &ldquo;Carnitine in Neonatal Nutrition,&rdquo; <i>J Child Neurol</i>, 1995, 10(Suppl 2):S25-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/8576565 /pubmed\" target=\"_blank\" id=\"8576565 \">8576565 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eknoyan G, Latos DL, and Lindberg J, &quot;Practice Recommendations for the Use of L-carnitine in Dialysis-Related Carnitine Disorder. National Kidney Foundation Carnitine Consensus Conference,&quot; <i>Am J Kidney Dis</i>, 2003, 41(4):868-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/12666074/pubmed\" target=\"_blank\" id=\"12666074\">12666074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eyer F, Felgenhauer N, Gempel K, et al, &quot;Acute Valproate Poisoning: Pharmacokinetics, Alteration in Fatty Acid Metabolism, and Changes During Therapy,&quot; <i>J Clin Psychopharmacol</i>, 2005, 25(4):376-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/16012283/pubmed\" target=\"_blank\" id=\"16012283\">16012283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freeman JM, Vining EP, Cost S, et al, &quot;Does Carnitine Administration Improve the Symptoms Attributed to Anticonvulsant Medications?: A Double-Blinded, Crossover Study,&quot; <i>Pediatrics</i>, 1994, 93(6 Pt 1):893-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/8190572/pubmed\" target=\"_blank\" id=\"8190572\">8190572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Helms RA, Mauer EC, and Hay WW Jr, &ldquo;Effect of Intravenous L-Carnitine on Growth Parameters and Fat Metabolism During Parenteral Nutrition in Neonates,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 1990, 14(5):448-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/2122016 /pubmed\" target=\"_blank\" id=\"2122016 \">2122016 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katiyar A and Aaron C, &quot;Case Files of the Children's Hospital of Michigan Regional Poison Control Center: The Use of Carnitine for the Management of Acute Valproic Acid Toxicity,&quot; <i>J Med Toxicol</i>, 2007, 3(3):129-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/18072149/pubmed\" target=\"_blank\" id=\"18072149\">18072149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI Work Group, &quot;KDOQI Clinical Practice Guideline for Nutrition in Children With CKD: 2008 Update. Executive Summary,&quot; <i>Am J Kidney Dis</i>, 2009, 53(3 Suppl 2):S11-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/19231749/pubmed\" target=\"_blank\" id=\"19231749\">19231749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&ouml;lker S, Christensen E, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I--revised recommendations. <i>J Inherit Metab Dis</i>. 2011;34(3):677-694.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/21431622/pubmed\" target=\"_blank\" id=\"21431622\">21431622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li BU, Lefevre F, Chelimsky GG, et al, &quot;North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2008, 47(3):379-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/18728540/pubmed\" target=\"_blank\" id=\"18728540\">18728540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. <i>Am J Med Genet C Semin Med Genet</i>. 2006;142C(2):77-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/16602102/pubmed\" target=\"_blank\" id=\"16602102\">16602102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. <i>Orphanet J Rare Dis</i>. 2012;7:68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/22989098/pubmed\" target=\"_blank\" id=\"22989098\">22989098</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mock CM and Schwetschenau KH, &quot;Levocarnitine for Valproic Acid-Induced Hyperammonemic Encephalopathy,&quot; <i>Am J Health Syst Pharm</i>, 2012, 69(1):35-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/22180549/pubmed\" target=\"_blank\" id=\"22180549\">22180549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &quot;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&quot; <i>Am J Kidney Dis</i>, 2006, 47(5 Suppl 3):S11-145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/16678659/pubmed\" target=\"_blank\" id=\"16678659\">16678659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrott J, Murphy NG, and Zed PJ, &quot;L-Carnitine for Acute Valproic Acid Overdose: A Systematic Review of Published Cases,&quot; <i>Ann Pharmacother</i>, 2010, 44(7-8):1287-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/20587742/pubmed\" target=\"_blank\" id=\"20587742\">20587742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russell S, &quot;Carnitine as an Antidote for Acute Valproate Toxicity in Children,&quot; <i>Curr Opin Pediatr</i>, 2007, 19(2):206-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/17496767/pubmed\" target=\"_blank\" id=\"17496767\">17496767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sutton VR, Chapman KA, Gropman AL, et al. Chronic management and health supervision of individuals with propionic acidemia. <i>Mol Genet Metab</i>. 2012;105(1):26-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-pediatric-drug-information/abstract-text/21963082/pubmed\" target=\"_blank\" id=\"21963082\">21963082</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13119 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187916\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187917\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059754\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442198\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059748\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187896\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F187881\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059758\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F187912\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059757\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187954\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187952\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14725394\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187885\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022070\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299590\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221274\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187892\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187904\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059753\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1059756\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187884\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F187901\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187903\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187906\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13119|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=carnitine-supplements-levocarnitine-drug-information\" class=\"drug drug_general\">Carnitine supplements (Levocarnitine): Drug information</a></li><li><a href=\"topic.htm?path=carnitine-supplements-levocarnitine-patient-drug-information\" class=\"drug drug_patient\">Carnitine supplements (Levocarnitine): Patient drug information</a></li></ul></div></div>","javascript":null}